Evidence map›Paper›PMID 14579152›Full record

ReviewEuropean journal of pediatrics2003

Glutaric aciduria type 1 and neonatal screening: time to proceed--with caution.

Andrea Superti-Furga

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of pediatrics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Neonatal screening for glutaryl-CoA dehydrogenase deficiency.Journal of inherited metabolic disease · 2004
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Andrea Superti-FurgaDivision of Molecular Paediatrics, CI-02-33, Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Switzerland. asuperti@chuv.unil.ch

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The new technology of tandem mass spectrometry is having a significant impact on the diagnostics of inborn metabolic errors. One of the most important aspects of this new technology is the possibility of recognising a whole class of disorders within a single analytical step. Shall this powerful technology be applied to the screening of newborn babies? Careful evaluation of every single disorder that could potentially be identified is needed. In the following, I will present some considerations that concern glutaric aciduria type 1 (MIM 231670; glutaryl-CoA dehydrogenase deficiency).

Indexed as

Amino Acid Metabolism, Inborn ErrorsBiomedical TechnologyGlutaratesGlutaryl-CoA DehydrogenaseHumansInfant, NewbornNeonatal ScreeningOxidoreductases Acting on CH-CH Group DonorsGlutaratesglutaric acidGlutaryl-CoA DehydrogenaseOxidoreductases Acting on CH-CH Group Donors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.